<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">07-PONE-RA-01926R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0000959</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Cell Biology</subject><subject>Chemical Biology</subject><subject>Developmental Biology</subject><subject>Cell Biology/Cell Growth and Division</subject><subject>Cell Biology/Cell Signaling</subject><subject>Cell Biology/Developmental Molecular Mechanisms</subject><subject>Chemical Biology/Small Molecule Chemistry</subject><subject>Developmental Biology/Cell Differentiation</subject><subject>Developmental Biology/Developmental Molecular Mechanisms</subject><subject>Developmental Biology/Embryology</subject><subject>Developmental Biology/Organogenesis</subject><subject>Developmental Biology/Stem Cells</subject><subject>Oncology/Skin Cancers</subject></subj-group></article-categories><title-group><article-title>The <italic>INT6</italic> Cancer Gene and MEK Signaling Pathways Converge during Zebrafish Development</article-title><alt-title alt-title-type="running-head">A Novel Int6-Mek Pathway</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Grzmil</surname><given-names>Michal</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Whiting</surname><given-names>Danny</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Maule</surname><given-names>John</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Anastasaki</surname><given-names>Corina</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Amatruda</surname><given-names>James F.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kelsh</surname><given-names>Robert N.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Norbury</surname><given-names>Chris J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Patton</surname><given-names>E. Elizabeth</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom</addr-line></aff><aff id="aff2"><label>2</label><addr-line>MRC Human Genetics Unit and University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Departments of Pediatrics, Internal Medicine and Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Centre for Regenerative Medicine, Developmental Biology Programme, Department of Biology and Biochemistry, University of Bath, Bath, United Kingdom</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Zwaka</surname><given-names>Thomas</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Baylor College of Medicine, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; To whom correspondence should be addressed. E-mail: <email>epatton@staffmail.ed.ac.uk</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: EP CN MG. Performed the experiments: JA EP JM CA MG DW. Analyzed the data: JA EP CN. Contributed reagents/materials/analysis tools: RK EP CN. Wrote the paper: EP.</p></fn></author-notes><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>26</day><month>9</month><year>2007</year></pub-date><volume>2</volume><issue>9</issue><elocation-id>e959</elocation-id><history><date date-type="received"><day>3</day><month>8</month><year>2007</year></date><date date-type="accepted"><day>2</day><month>9</month><year>2007</year></date></history><copyright-statement>Grzmil et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2007</copyright-year><abstract><sec><title>Background</title><p><italic>Int-6</italic> (integration site 6) was identified as an oncogene in a screen of tumorigenic mouse mammary tumor virus (MMTV) insertions. <italic>INT6</italic> expression is altered in human cancers, but the precise role of disrupted <italic>INT6</italic> in tumorigenesis remains unclear, and an animal model to study <italic>Int-6</italic> physiological function has been lacking.</p></sec><sec><title>Principal Findings</title><p>Here, we create an <italic>in vivo</italic> model of Int6 function in zebrafish, and through genetic and chemical-genetic approaches implicate Int6 as a tissue-specific modulator of MEK-ERK signaling. We find that Int6 is required for normal expression of MEK1 protein in human cells, and for Erk signaling in zebrafish embryos. Loss of either Int6 or Mek signaling causes defects in craniofacial development, and Int6 and Erk-signaling have overlapping domains of tissue expression.</p></sec><sec><title>Significance</title><p>Our results provide new insight into the physiological role of vertebrate Int6, and have implications for the treatment of human tumors displaying altered <italic>INT6</italic> expression.</p></sec></abstract><counts><page-count count="6"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Embryonic development and tumour development often share underlying molecular mechanisms&#x02013;a concept illustrated by the identification of genes disrupted by the mouse mammary tumor virus (MMTV) in mammary cancers <xref ref-type="bibr" rid="pone.0000959-Callahan1">&#x0005b;1&#x0005d;</xref>. An important example, the <italic>Int-1</italic> gene which is a common integration site for MMTV in mammary tumours, encodes the homologue of the <italic>Drosophila wingless</italic> gene <xref ref-type="bibr" rid="pone.0000959-Nusse1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0000959-Rijsewijk1">&#x0005b;3&#x0005d;</xref> and was subsequently named <italic>Wnt1</italic> (wingless/Int) in recognition of this conserved function. Wnt signaling is now known to be disrupted in many human tumor types, especially colon cancer <xref ref-type="bibr" rid="pone.0000959-Clevers1">&#x0005b;4&#x0005d;</xref>. Other <italic>Int</italic> genes, such as <italic>Int-2</italic> and <italic>4</italic> (Fgf3, 4), and <italic>Int-3</italic> (Notch4), encode mitogens and regulators of development that are also misactivated in many cancers <xref ref-type="bibr" rid="pone.0000959-Callahan1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0000959-Tekmal1">&#x0005b;5&#x0005d;</xref>.</p><p>In the majority of cases, MMTV activates <italic>Int</italic> gene expression as a result of proviral integration upstream of the promoter region. Remarkably, all three MMTV insertions found in <italic>Int-6</italic>, which encodes a component of the eukaryotic translation initation factor 3 (eIF3), were found to lie within introns, and in the opposite transcriptional orientation to the <italic>Int-6</italic> gene, creating a truncated <italic>Int-6</italic> mRNA <xref ref-type="bibr" rid="pone.0000959-Callahan1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0000959-Asano1">&#x0005b;6&#x0005d;</xref>. Ectopic expression of equivalently truncated <italic>Int-6</italic> can transform cell cultures <xref ref-type="bibr" rid="pone.0000959-Mayeur1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0000959-Rasmussen1">&#x0005b;8&#x0005d;</xref>, and promote persistent mammary alveolar hyperplasia and tumorigenesis in transgenic mice <xref ref-type="bibr" rid="pone.0000959-Mack1">&#x0005b;9&#x0005d;</xref>.</p><p>Despite important evidence in favor of a role for INT6 in human tumourigenesis <xref ref-type="bibr" rid="pone.0000959-Buttitta1">&#x0005b;10&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0000959-TraicoffChung1">&#x0005b;12&#x0005d;</xref>, the molecular basis for INT6 in cancer development remains unresolved. Highly conserved in eukaryotes, INT6 contains a PCI domain, found in proteins of the 19S regulatory lid of the <underline>p</underline>roteasome, the <underline>C</underline>OP9 signalosome (CSN), and the e<underline>I</underline>F3 translation initiation complex; all three complexes share overall structural similarity, and INT6 has been found associated with each <xref ref-type="bibr" rid="pone.0000959-Yen1">&#x0005b;13&#x0005d;</xref>. When overexpressed in yeast, Int6 induces multi-drug resistance by activating an AP-1 transcription factor <xref ref-type="bibr" rid="pone.0000959-Crane1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0000959-Jenkins1">&#x0005b;15&#x0005d;</xref>, and in human cells, the range of INT6 function includes orderly progression through mitosis <xref ref-type="bibr" rid="pone.0000959-Morris1">&#x0005b;16&#x0005d;</xref>, regulation of the proteasome-dependent stability of MCM7 <xref ref-type="bibr" rid="pone.0000959-Buchsbaum1">&#x0005b;17&#x0005d;</xref> and HIF2&#x003b1; <xref ref-type="bibr" rid="pone.0000959-Chen1">&#x0005b;18&#x0005d;</xref>, and nonsense mediated mRNA decay <xref ref-type="bibr" rid="pone.0000959-Morris2">&#x0005b;19&#x0005d;</xref>.</p><p>With no animal model for Int6 loss-of-function available, we reasoned that an understanding of <italic>INT6</italic> during development would provide novel insight into INT6 function in normal vertebrate cells, thereby providing a new perspective on INT6 function in cancer formation. Here, using zebrafish and mammalian cells, we describe the first Int6 loss-of-function phenotype in an animal, and link Int6 with a signaling pathway, that like those effected by other <italic>Int</italic> genes, is critical for both development and cancer.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Int6 is essential for zebrafish embryogenesis</title><p>We chose to study the physiological role of zebrafish Int6 during development, using morpholino oligonucleotides (MOs) to reduce Int6 protein, as well as an <italic>int6<sup>hi2470</sup></italic> insertional mutant line (kindly provided by N. Hopkins, A. Amsterdam and S. Farrington. M.I.T.). Zebrafish Int6 is over 90&#x00025; identical in its amino acid sequence to human INT6 (<italic>Ensembl</italic> ENSDARG00000002549) and using an Int6 antibody raised against the N-terminus of the human INT6 <xref ref-type="bibr" rid="pone.0000959-Watkins1">&#x0005b;20&#x0005d;</xref> we determined that the <italic>int6</italic> MO resulted in loss of Int6 (<xref ref-type="fig" rid="pone-0000959-g001">Figure 1A</xref>). As INT6 has been implicated in G2/M-phase cell cycle control, we first performed whole-mount immunohistochemistry with the late G2/M phase marker, phospho-histone H3, and found only slightly reduced numbers of cells in late G2/M phase in the <italic>int6</italic> morphant compared to the control (<xref ref-type="supplementary-material" rid="pone.0000959.s001">Figure S1</xref>). Importantly, we found that embryos injected with <italic>int6</italic> MO had specific developmental defects (<xref ref-type="fig" rid="pone-0000959-g001">Figure 1B&#x02013;N</xref>), most notably reduced melanisation 2 days post-fertilization (dpf: <italic>int-6</italic> MO n&#x0200a;&#x0003d;&#x0200a;51/53; con MO n&#x0200a;&#x0003d;&#x0200a;0/35; <italic>int-6 5MM</italic> n&#x0200a;&#x0003d;&#x0200a;3/31); misplaced pigment cells in the tail 3 dpf (<italic>int-6</italic> MO n&#x0200a;&#x0003d;&#x0200a;46/49; con MO n&#x0200a;&#x0003d;&#x0200a; 3/30); and abnormal jaw morphogenesis, with cartilage elements reduced or malformed at 4 and 5 dpf (<italic>int-6</italic> MO n&#x0200a;&#x0003d;&#x0200a;81/85 4 dpf, n&#x0200a;&#x0003d;&#x0200a;76/83 5 dpf; con MO 1/67 4 dpf, n&#x0200a;&#x0003d;&#x0200a;1/61 5 dpf). The craniofacial and pigment cell defects observed in the <italic>int-6</italic> morphant and <italic>hi2470</italic> mutant suggest that <italic>int-6</italic> might contribute to development of neural crest-cell (NCC) derivatives. We used multiple markers of NCCs and their derivatives to assess when these phenotypes arise, and found Int6 did not appear to be required for the specification or organization of premigratory and migrating cartilage precursors (<xref ref-type="supplementary-material" rid="pone.0000959.s002">Figure S2</xref>). In contrast, alcian blue cartilage staining revealed a specific loss of the five ceratobranchial cartilage elements in the <italic>int6</italic> morphants, whereas Meckel's, palatoquadrate, and hyoid cartilage were all present, albeit misshapen (5.5 dpf <italic>int6</italic> MO n&#x0200a;&#x0003d;&#x0200a;45/53; con MO n&#x0200a;&#x0003d;&#x0200a;1/34; <xref ref-type="fig" rid="pone-0000959-g001">Figure 1I&#x02013;L</xref>, <xref ref-type="supplementary-material" rid="pone.0000959.s003">Figure S3</xref>). Expression of <italic>int6</italic> mRNA restored normal craniofacial elements to the <italic>int6</italic> morphant (<italic>data not shown</italic>); and the <italic>int6<sup>hi2470</sup></italic> mutant had an almost identical craniofacial phenotype (<xref ref-type="fig" rid="pone-0000959-g001">Figure 1M, N</xref>) indicating a genuine requirement for Int6 in craniofacial development.</p><fig id="pone-0000959-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0000959.g001</object-id><label>Figure 1</label><caption><title>Int6 is essential for zebrafish embryonic development.</title><p>(A) Western blot analysis of Int6 (&#x0002a;) in zebrafish embryos injected with a control (con) MO or <italic>int6</italic> MO. (B) <italic>int6</italic> morphant melanocytes are less darkly pigmented. (C&#x02013;F) Int6 is required for pigment cell placement in the tail, as <italic>int6</italic> morphants and <italic>int6<sup>hi2470</sup></italic> mutants have misplaced pigment cells in the tail fin (D, arrow). Ambient light illuminates the iridophore &#x02018;star-light&#x02019; pattern seen in the <italic>int6<sup>hi2470</sup></italic> embryos (F, arrow). (G&#x02013;H) By 5 dpf, embryos injected with a con MO have clearly visible certobranical arches, while <italic>int6</italic> morphants do not have visible certobranical arches, in addition to other abnormalities, including unconsumed yolk sac, heart and eye development. (I&#x02013;N). Alcian blue staining of 5 dpf embryos shows loss of ceratobrancial arches 1 through 5. M, Meckel's; PQ, palatoquadrate; CH, ceratohyal; CB, ceratobrancial.</p></caption><graphic xlink:href="pone.0000959.g001"/></fig></sec><sec id="s2b"><title>Loss of Int6 alters MEK protein and Erk signaling</title><p>Biochemical evidence in fission yeast suggests that Int6 is part of a specialized eIF3 translation initiation complex that may target specific mRNAs for translation <xref ref-type="bibr" rid="pone.0000959-Zhou1">&#x0005b;21&#x0005d;</xref>. Given the involvement of INT6 in cell proliferation <xref ref-type="bibr" rid="pone.0000959-Morris1">&#x0005b;16&#x0005d;</xref>, western blots using a panel of antibodies against proteins involved in the cell cycle and associated signalling pathways were performed using lysates from control and INT6 siRNA transfected MDA-MB-231 cells. Of 16 proteins investigated in this way, only MEK1 levels were altered by INT6 siRNA transfection (<xref ref-type="fig" rid="pone-0000959-g002">Figure 2</xref>). As previously reported <xref ref-type="bibr" rid="pone.0000959-Watkins1">&#x0005b;20&#x0005d;</xref>, we found <italic>INT6</italic>-siRNA cell lysates had reduced levels of INT6 protein compared with the untransfected and reverse <italic>INT6</italic>-siRNA sequence. We also found a dramatic reduction of MEK1 protein levels that correlated with loss of INT6, while BAX, tubulin and actin protein levels appeared unaffected in the <italic>INT6</italic>-siRNA transfected cells (<xref ref-type="fig" rid="pone-0000959-g002">Figure 2A</xref>). The loss of MEK1 was specifically at the protein level, as semi-quantitative-PCR showed normal levels of <italic>MEK1</italic> mRNA in <italic>INT6</italic>-siRNA treated cells, as well as the expected reduced levels of the INT6 message in the <italic>INT6</italic>-siRNA transfected cells (<xref ref-type="fig" rid="pone-0000959-g002">Figure 2B</xref>). The possibility that <italic>INT6</italic> may affect MAPK signaling through control of MEK protein levels prompted us to examine the phosphorylation state of Erk1/2, downstream targets of the Mek kinases, in <italic>int6</italic> morphant zebrafish embryos. Compared with control MO embryos, <italic>int6</italic> morphant embryo lysates had reduced phospho-Erk levels (<xref ref-type="fig" rid="pone-0000959-g002">Figure 2C</xref>). These data suggest a novel function for Int6 in the control of MAPK signaling in the developing embryo, possibly by direct control of MEK1 protein levels.</p><fig id="pone-0000959-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0000959.g002</object-id><label>Figure 2</label><caption><title>INT6 is required for MEK protein levels and Erk-signaling.</title><p>A. Osteosarcoma U2-OS cells untransfected (U), or transfected with siRNA targeted against the <italic>INT6</italic> mRNA (si) or the reverse sequence (R), show reduced levels of INT6 and MEK1 protein specifically after transfection with <italic>INT6-</italic>siRNA, but no reduction in BAX, tubulin or actin protein levels. (B) Semi-quantitative-PCR shows <italic>MEK1</italic> mRNA is unaffected in reverse sequence and <italic>INT6</italic>-siRNA treated cells, coupled with the expected reduced levels of the <italic>INT6</italic> message in the <italic>INT6</italic>-siRNA transfected cells. c, PCR control without DNA. (C) Phospho-Erk levels are reduced in <italic>int6</italic> morphants, while ponceau stain detects equal loading of protein on the gel.</p></caption><graphic xlink:href="pone.0000959.g002"/></fig></sec><sec id="s2c"><title>Int6 and Mek pathways converge during development</title><p>If Int6 controls Mek activity in the developing embryo, we theorized that specific developing tissues might have overlapping expression domains of Int6 protein and phospho-Erk activity. Indeed, immunohistochemistry with antibodies directed against Int6 and phospho-Erk revealed overlapping domains of expression in the developing craniofacial region in 3 and 4 dpf embryos (<xref ref-type="fig" rid="pone-0000959-g003">Figure 3A&#x02013;F</xref>). Strong Int6 tissue-specific expression was also detected in the developing intestine and lens, regions that had little or no phospho-Erk expression (<xref ref-type="supplementary-material" rid="pone.0000959.s004">Figure S4</xref>). Given the observed phospho-Erk and Int6 expression in the craniofacial region, we hypothesized that some of the Int6 phenotypes, such as the jaw formation defect, might be phenocopied by repression of Erk signaling. As interpretation of MO phenotypes has recently been complicated by the identification of MO-induced p53-dependent craniofacial defects <xref ref-type="bibr" rid="pone.0000959-Robu1">&#x0005b;22&#x0005d;</xref>, we used an alternative approach &#x02013; the highly selective, clinically active MEK inhibitor CI-1040 <xref ref-type="bibr" rid="pone.0000959-SeboltLeopold1">&#x0005b;23&#x0005d;</xref> &#x02013; to reduce Mek signaling in zebrafish. We added the drug at 4 hpf at a concentration of 0.25, 0.5, and 1.0 &#x000b5;M, and confirmed loss of phospho-Erk expression by Western blot analysis (<italic>data not shown</italic>). Notably, the addition of CI-1040 caused a dose-dependent loss of the posterior structures of the embryo, such that 1.0 &#x000b5;M CI-1040 caused a severe anterior-posterior (AP) axis defect (<xref ref-type="fig" rid="pone-0000959-g004">Figure 4A&#x02013;C</xref>), consistent with a role for FGF signaling in the development of the AP axis <xref ref-type="bibr" rid="pone.0000959-Schier1">&#x0005b;24&#x0005d;</xref>. CI-1040 also caused loss of ceratobranchial cartilage elements, while the anterior elements &#x02013; Meckel's, palatoquadrate and hyoid cartilages &#x02013; were present but misshapen (<xref ref-type="fig" rid="pone-0000959-g003">Figure 3G&#x02013;J</xref>), similar to the effects seen in <italic>int6</italic> morphants and mutants.</p><fig id="pone-0000959-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0000959.g003</object-id><label>Figure 3</label><caption><title>Int6 and phospho-Erk expression in the developing zebrafish embryo, and pharmacological inhibition of Mek alters ceratobrancial (CB) arches.</title><p>(A&#x02013;F). Immuno-histochemistry of Int6 and phospho-Erk in the developing craniofacial tissues, counter stained with hematoxylin, and phospho-histone H3 to show cycling cells. (G, H) Ventral whole mount views of Alcian blue stained pharyngeal cartilages show loss of ceratobrancial arches 1&#x02013;5 and a reduction of Meckel's (M), palatoquadrate (PQ) and ceratohyal (CH) cartilages in 4 dpf embryos treated with 0.5 uM CI-1040. (I, J) Sections of 4 dpf embryos hematoxylin and eosin stained after 0.5 uM CI-1040 treatment reveals loss of CB arches 1&#x02013;5 (brackets). E, Ethmoid plate; PC, Parachordal cartilage.</p></caption><graphic xlink:href="pone.0000959.g003"/></fig><p>To further elucidate the biological relevance of Int6 and Mek signaling, we took advantage of the ease with which signaling pathways can be altered pharmacologically in specific genetic contexts in the zebrafish system. We reasoned that if Int6 contributes to activation of Mek signaling, then embryos with reduced Int6 should be hypersensitive to low doses of the MEK inhibitor CI-1040. In control embryos treated with 0.25 &#x000b5;M CI-1040, no changes in the anterior-posterior axis were detected (<xref ref-type="fig" rid="pone-0000959-g004">Figure 4B</xref>). In addition, <italic>int6</italic> morphants generated by low doses of MO (0.25 ng) did not have an altered AP axis (<xref ref-type="fig" rid="pone-0000959-g004">Figure 4D</xref>). In contrast, in combination with low doses of CI-1040, the low dose <italic>int6</italic> morphant showed a severely enhanced AP axis phenotype (<xref ref-type="fig" rid="pone-0000959-g004">Figure 4E</xref>). Taken together, these data provide further evidence that <italic>int6</italic> may play a role in modulating MEK signaling <italic>in vivo</italic>.</p><fig id="pone-0000959-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0000959.g004</object-id><label>Figure 4</label><caption><title>Int6 and Mek signaling interact <italic>in vivo</italic>.</title><p>(A&#x02013;C). Only embryos treated with the 1.0 &#x000b5;M CI-1040, and not 0.25 &#x000b5;M, show a loss of posterior structures, in contrast to (D) <italic>int6</italic> morphants (<italic>int6</italic> MO 0.25 ng). (E, F) In combination with 0.25 &#x000b5;M of CI-1040, 0.25 &#x000b5;g of <italic>int6</italic> MO causes a dramatic alteration of the anterior-posterior axis.</p></caption><graphic xlink:href="pone.0000959.g004"/></fig></sec></sec><sec id="s3"><title>Discussion</title><p>Activated in most cancers, the MAPK signaling pathway is among the most attractive targets for novel anti-cancer therapies <xref ref-type="bibr" rid="pone.0000959-SeboltLeopold1">&#x0005b;23&#x0005d;</xref>. Like MAPK signaling pathways, most of the <italic>Int</italic> pathways - Wnt, Fgf, and Notch - are conserved regulators of development that are frequently activated to promote oncogenesis. We provide evidence that, like other <italic>Int</italic> gene products, <italic>Int6</italic> is required for vertebrate development (<xref ref-type="fig" rid="pone-0000959-g001">Figure 1</xref>), in part by providing a novel layer of MAPK signal transduction regulation (<xref ref-type="fig" rid="pone-0000959-g002">Figure 2</xref>). With the wide range of cellular activities attributed to INT6, the mechanistic detail of this control remains to be understood; our early investigations indicate reduction of MEK1 in <italic>INT6</italic>-siRNA treated mammalian cells is not dependent on the proteasome (M.G. &#x00026; C.J.N., <italic>unpublished data</italic>), making direct MEK1 regulation by INT6-dependent translation a possibility.</p><p>Recently, importance of RAS, RAF and MEK in human disease has been extended beyond cancer by the discovery that human germ-line mutations in these genes cause the LEOPARD-Noonan family of syndromes <xref ref-type="bibr" rid="pone.0000959-BentiresAlj1">&#x0005b;25&#x0005d;</xref>. Detailed immunohistochemical studies in mice have identified highly regulated, specific domains of discrete and dynamic ERK phosphorylation throughout development, including the pharyngeal arches and limb buds <xref ref-type="bibr" rid="pone.0000959-Corson1">&#x0005b;26&#x0005d;</xref>. In the first Int6 protein expression studies in a whole developing animal, we show that Int6 has regionally overlapping domains of protein expression with phospho-Erk, primarily in the craniofacial region (<xref ref-type="fig" rid="pone-0000959-g003">Figure 3</xref>, <xref ref-type="supplementary-material" rid="pone.0000959.s004">Figure S4</xref>). Lending biological significance to these observations, we show that phenotypic characteristics are shared between the loss of Int6 and inhibition of Mek activity (<xref ref-type="fig" rid="pone-0000959-g003">Figure 3</xref>). In addition, partial loss of Int6 causes embryos to be highly sensitive to a mildly compromising dose of Mek inhibition, revealing an <italic>in vivo</italic> interaction between Int6 protein expression and developmental Mek-Erk signaling (<xref ref-type="fig" rid="pone-0000959-g004">Figure 4</xref>). As early over-expression of Ras-Raf-Mek signaling causes morphologic defects, we are currently generating transgenic lines that allow temporal control of Mek signaling, which will be a valuable tool for deeper genetic dissection of the Int6-Mek-Erk relationship <italic>in vivo</italic>. It will be critical in future studies to establish if Int6 is capable of controlling both Mek1 and Mek2; our initial MO studies indicate that MEK2 may have a specific role in melanocyte migration (C.A. &#x00026; E.E.P, <italic>unpublished data</italic>), raising the possibility that the pigment cell migration defects observed in the <italic>int6</italic> morphants also reflect altered MEK signaling.</p><p>FGF signaling is crucial for skeletal development, exemplified by the mutations that disrupt FGF signaling in human genetic skeletal abnormality syndromes <xref ref-type="bibr" rid="pone.0000959-Wilkie1">&#x0005b;27&#x0005d;</xref>. In the developing mouse embryo, most phospho-ERK domains overlap with FGF signaling domains <xref ref-type="bibr" rid="pone.0000959-Corson1">&#x0005b;26&#x0005d;</xref>. FGF signaling molecules are candidates for upstream activation of the Int6-moderated Mek-Erk signaling that shapes the craniofacial skeleton in vertebrates <xref ref-type="bibr" rid="pone.0000959-Goldring1">&#x0005b;28&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0000959-Graham1">&#x0005b;29&#x0005d;</xref>, and candidate downstream targets of Int6-Mek-Erk signaling include the chondrocyte differentiation transcription factor Sox9, which requires Mek activity for transcriptional activity <xref ref-type="bibr" rid="pone.0000959-Murakami1">&#x0005b;30&#x0005d;</xref>. We also note that <italic>erk2</italic>, but not <italic>erk1</italic>, is specifically expressed in the pharyngeal arches in two-day old zebrafish embryos <xref ref-type="bibr" rid="pone.0000959-Krens1">&#x0005b;31&#x0005d;</xref>, possibly suggesting that Int6-Mek modulation in the developing craniofacial region may specifically signal through targets of Erk2.</p><p>Relating the Int6 modulation of Mek-Erk signaling to cancer development is a new angle for future investigation. One possibility is that in MMTV induced mammary tumors, the truncated Int-6 protein may act as an oncogene by altering MEK-ERK signaling. We propose that the diverse cellular locations of Int6, combined with the temporal expression and localization of Mek1/2 and Erk1/2, may result in fine-tuning of Mek-Erk signaling pathways in specific tissues during development, and may have important implications for the role of INT6 in tumorigenesis.</p></sec><sec sec-type="methods" id="s4"><title>Methods</title><sec id="s4a"><title>Zebrafish husbandry and morpholino studies</title><p>Zerbafish (<italic>Danio rerio</italic>) lines AB, AB&#x0002a;, and AB&#x0002a;-TPL were raised and staged as described <xref ref-type="bibr" rid="pone.0000959-Westerfield1">&#x0005b;32&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0000959-Kimmel1">&#x0005b;33&#x0005d;</xref>. MOs (<xref ref-type="table" rid="pone-0000959-t001">Table 1</xref>) were designed by and purchased from Gene Tools, LLC (USA), and 1 ng injected into one-cell stage embryos.</p><table-wrap id="pone-0000959-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0000959.t001</object-id><label>Table 1</label><caption><title>Oligonucleotides used in this study</title></caption><graphic id="pone-0000959-t001-1" xlink:href="pone.0000959.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0000959-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><italic>Method</italic></td><td align="left" rowspan="1" colspan="1"><italic>Symbol</italic></td><td align="left" rowspan="1" colspan="1"><italic>Oligonucleotide</italic></td></tr></thead><tbody><tr><td colspan="3" align="left" rowspan="1"><italic>Morpholino</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Control</td><td align="left" rowspan="1" colspan="1"><italic>con</italic> MO</td><td align="left" rowspan="1" colspan="1">5&#x02032; <named-content content-type="gene">CCTCTTACCTCAGTTACAATTTATA</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>int6</italic> Translation block</td><td align="left" rowspan="1" colspan="1"><italic>int-6</italic> MO</td><td align="left" rowspan="1" colspan="1">5&#x02032; <named-content content-type="gene">GGTCAGATCGTACTCCGCCATGATG</named-content></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>int6</italic> 5-base pair mismatch</td><td align="left" rowspan="1" colspan="1"><italic>int-6</italic> 5MM</td><td align="left" rowspan="1" colspan="1">5&#x02032; GGTgAGATCcTAgTCCGCgATcATG</td></tr><tr><td colspan="3" align="left" rowspan="1"><italic>siRNA</italic></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>INT6</italic> sense siRNA (si)</td><td align="left" rowspan="1" colspan="1"><italic>INT6</italic>-siRNA</td><td align="left" rowspan="1" colspan="1">5&#x02032; GAACCACAGUGGUUGCACAUU</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>INT6</italic> reverse siRNA (R)</td><td align="left" rowspan="1" colspan="1">R</td><td align="left" rowspan="1" colspan="1">5&#x02032; UUACACGUUGGUGACACCAAG</td></tr><tr><td colspan="3" align="left" rowspan="1"><italic>RT-PCR primers</italic></td></tr><tr><td colspan="2" align="left" rowspan="1">&#x02003;&#x02003;&#x02003;<italic>MEK1</italic> forward</td><td align="left" rowspan="1" colspan="1">5&#x02032; <named-content content-type="gene">ATTATTGTTCCCCTAAGTGGATTG</named-content></td></tr><tr><td colspan="2" align="left" rowspan="1">&#x02003;&#x02003;&#x02003;<italic>MEK1</italic> reverse</td><td align="left" rowspan="1" colspan="1">5&#x02032; <named-content content-type="gene">TTACAACAGCATTGGTACTTGGAT</named-content></td></tr><tr><td colspan="2" align="left" rowspan="1">&#x02003;&#x02003;&#x02003;<italic>INT6</italic> forward</td><td align="left" rowspan="1" colspan="1">5&#x02032; <named-content content-type="gene">ATGGCGGAGTACGACTTGACT</named-content></td></tr><tr><td colspan="2" align="left" rowspan="1">&#x02003;&#x02003;&#x02003;<italic>INT6</italic> reverse</td><td align="left" rowspan="1" colspan="1">5&#x02032; <named-content content-type="gene">TCAGTAGAAGCCAGAATCTTGAGT</named-content></td></tr><tr><td colspan="2" align="left" rowspan="1">&#x02003;&#x02003;&#x02003;<italic>Actin</italic> forward</td><td align="left" rowspan="1" colspan="1">5&#x02032; <named-content content-type="gene">CGTGATGGTGGGCATGGGTCA</named-content></td></tr><tr><td colspan="2" align="left" rowspan="1">&#x02003;&#x02003;&#x02003;<italic>Actin</italic> reverse</td><td align="left" rowspan="1" colspan="1">5&#x02032; <named-content content-type="gene">CTTAATGTCACGCACGATTTCC</named-content></td></tr></tbody></table></table-wrap></sec><sec id="s4b"><title>Phenotype analysis</title><p>Phenotype analysis were performed as described: cell cycle studies <xref ref-type="bibr" rid="pone.0000959-Shepard1">&#x0005b;34&#x0005d;</xref>; alcian blue staining <xref ref-type="bibr" rid="pone.0000959-Javidan1">&#x0005b;35&#x0005d;</xref>; probe synthesis and whole-mount in-situ hybridizations <xref ref-type="bibr" rid="pone.0000959-NussleinVolhard1">&#x0005b;36&#x0005d;</xref>. cDNA probes for neural crest markers were the kind gift of David Raible (University of Washington, USA). Polyadenylated <italic>int6</italic> mRNA was generated using Ambion mMessage mMachine (#1340).</p></sec><sec id="s4c"><title>Cell culture and RT-PCR analysis</title><p>MDA-MB-231 cells were grown and transfected as described <xref ref-type="bibr" rid="pone.0000959-Morris2">&#x0005b;19&#x0005d;</xref> using Lipofectamine (Invitrogen) with si-oligonucleotides (<xref ref-type="table" rid="pone-0000959-t001">Table 1</xref>; Eurogentec) at a final concentration of 100 nM in Optimem (Gibco). Forty-eight hours after transfection total RNA was isolated (RNeasy Mini Kit; Qiagen) and one-step RT-PCR reactions (Qiagen) accomplished using specific primers (<xref ref-type="table" rid="pone-0000959-t001">Table 1</xref>).</p></sec><sec id="s4d"><title>Immunoblotting</title><p>Whole-cell lysates and zebrafish extracts were generated <xref ref-type="bibr" rid="pone.0000959-Krens1">&#x0005b;31&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0000959-Morris2">&#x0005b;19&#x0005d;</xref> and immunohistochemistry was performed as described <xref ref-type="bibr" rid="pone.0000959-NussleinVolhard1">&#x0005b;36&#x0005d;</xref>. Antibodies used as in <xref ref-type="table" rid="pone-0000959-t002">Table 2</xref>.</p><table-wrap id="pone-0000959-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0000959.t002</object-id><label>Table 2</label><caption><title>Primary antibodies used in this study</title></caption><graphic id="pone-0000959-t002-2" xlink:href="pone.0000959.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0000959-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"><italic>Antibody</italic></td><td align="left" rowspan="1" colspan="1"><italic>Source</italic></td><td align="left" rowspan="1" colspan="1"><italic>Working dilution</italic></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">anti-Phospho-Histone H3 (ser 10) #9706</td><td align="left" rowspan="1" colspan="1">Cell Signaling Technology</td><td align="left" rowspan="1" colspan="1">1&#x02236;1000 western blot 1&#x02236;100 immunohistochemistry</td></tr><tr><td align="left" rowspan="1" colspan="1">anti-Phospho-p44/42 MAPK #9160</td><td align="left" rowspan="1" colspan="1">Cell Signaling Technology</td><td align="left" rowspan="1" colspan="1">1&#x02236;1000 western blot 1&#x02236;100 immunohistochemistry</td></tr><tr><td align="left" rowspan="1" colspan="1">anti-Int6 CN24</td><td align="left" rowspan="1" colspan="1">Watkins and Norbury, 2004</td><td align="left" rowspan="1" colspan="1">1&#x02236;500 western blot 1&#x02236;50 immunohistochemistry</td></tr><tr><td align="left" rowspan="1" colspan="1">anti-&#x003b1;-tubulin</td><td align="left" rowspan="1" colspan="1">K. Gull, Oxford</td><td align="left" rowspan="1" colspan="1">1&#x02236;5000 western blot</td></tr><tr><td align="left" rowspan="1" colspan="1">anti-BAX N-20</td><td align="left" rowspan="1" colspan="1">Santa Cruz Biotechnology</td><td align="left" rowspan="1" colspan="1">1&#x02236;1000 western blot</td></tr><tr><td align="left" rowspan="1" colspan="1">anti-MEK1 H-8</td><td align="left" rowspan="1" colspan="1">Santa Cruz Biotechnology</td><td align="left" rowspan="1" colspan="1">1&#x02236;2000 western blot</td></tr><tr><td align="left" rowspan="1" colspan="1">anti-actin N-20</td><td align="left" rowspan="1" colspan="1">Sigma</td><td align="left" rowspan="1" colspan="1">1&#x02236;4000 western blot</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0000959.s001"><label>Figure S1</label><caption><p>Cell cycle analysis of int6 morphants. Whole-mount immunohistochemistry with the late G2/M phase marker, phospho-histone H3 shows only slightly reduced numbers of cells in late G2/M phase in the int6 morphant compared to the control. Similarly, DNA content as measured by flow cytometry reveals only a slight reduction of cells in G2/M phase in the int6 morphant. Thus, we find that loss of Int6 in normal vertebrate cells (as well as in additional human cancer cell lines, M.G. &#x00026; C.J.N. unpublished data) does not appear result in an accumulation of cells in G2/M progression.</p><p>(4.75 MB TIF)</p></caption><media xlink:href="pone.0000959.s001.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0000959.s002"><label>Figure S2</label><caption><p>Lateral views of in situ hybridization of neural crest markers in control and int6 morphants, revealing no change in cell number or migration as indicated by the apparently normal expression of dlx2 (stages 6&#x02013;36 hpf, examined at two hour intervals), nor of early markers of NCC and melanocytes, such as sox10, crestin, snail and mitfa (24 hpf) in int6 morphants. These observations were extended by examination of a transgenic sox10-GFP line (1) revealing unaltered GFP-expressing NC-derived cells in int6 morphants within the first 48 hpf, but a loss of GFP expressing differentiated pharyngeal arches 3&#x02013;7 by 3 dpf (data not shown).</p><p>(40.41 MB TIF)</p></caption><media xlink:href="pone.0000959.s002.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0000959.s003"><label>Figure S3</label><caption><p>Development of the pharyngeal arches in the developing control (A&#x02013;C) and (D&#x02013;F) int6 morphant animals. Note the loss of pharyngeal arches (A, bracket) in the int6 morphants (bracket). Sections were stained with methylene blue. Anterior to the left.</p><p>(14.09 MB TIF)</p></caption><media xlink:href="pone.0000959.s003.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0000959.s004"><label>Figure S4</label><caption><p>Immunohistochemistry of Int6 and phospho-Erk staining in 4 dpf embryos. (A, B) While Int6 and phospho-Erk signaling overlap in the craniofacial region, they also have distinct patterns, for example in the eye and (C, D) gut. We note that while Int6 and phospho-Erk have overlapping domains of expression in the craniofacial region, Int6 staining in the craniofacial region was stronger than phospho-Erk, and phospho-Erk staining was limited to specific tissues within the craniofacial region. M, Meckel's; E: Ethmoid plate; CH, ceratohyal; CB, ceratobrancial. Sagittal section, anterior to the left.</p><p>(17.60 MB TIF)</p></caption><media xlink:href="pone.0000959.s004.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We are grateful to N. Hopkins, A. Amsterdam and S. Farrington for the <italic>int6<sup>hi2470</sup></italic> line; R. Marais and C. Marshall for CI-1040; D. Raible for DNA constructs; K. Gull for anti-tubulin antibodies; E. Prichard for additional CI-1040 observations; D. Faratian for help with immunohistochemistry; B. Morgan for assistance with manuscript preparation; L. Poulton for critical reading of the manuscript; and N. Hastie and D. Harrison for helpful discussions.</p></ack><ref-list><title>References</title><ref id="pone.0000959-Callahan1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Callahan</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>GH</given-names></name></person-group><year>2000</year><article-title>MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways.</article-title><source>Ongogene</source><volume>19</volume><fpage>992</fpage><lpage>1001</lpage></citation></ref><ref id="pone.0000959-Nusse1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nusse</surname><given-names>R</given-names></name><name><surname>Varmus</surname><given-names>HE</given-names></name></person-group><year>1982</year><article-title>Many Tumors Induced by the Mouse Mammary Tumor Virus Contain a Provirus Integrated in the Same Region of the Host Genome.</article-title><source>Cell</source><volume>31</volume><fpage>99</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">6297757</pub-id></citation></ref><ref id="pone.0000959-Rijsewijk1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rijsewijk</surname><given-names>F</given-names></name><name><surname>Schuermann</surname><given-names>M</given-names></name><name><surname>Wagenaar</surname><given-names>E</given-names></name><name><surname>Parren</surname><given-names>P</given-names></name><name><surname>Weigel</surname><given-names>D</given-names></name><etal/></person-group><year>1987</year><article-title>The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless.</article-title><source>Cell</source><volume>50</volume><fpage>649</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">3111720</pub-id></citation></ref><ref id="pone.0000959-Clevers1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year>2006</year><article-title>Wnt/&#x000df;-Catenin Signaling in Development and Disease.</article-title><source>Cell</source><volume>3</volume><fpage>469</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">17081971</pub-id></citation></ref><ref id="pone.0000959-Tekmal1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tekmal</surname><given-names>RR</given-names></name><name><surname>Keshava</surname><given-names>N</given-names></name></person-group><year>1997</year><article-title>Role of MMTV integration locus cellular genes in breast cancer.</article-title><source>Front Biosci</source><volume>379</volume><fpage>519</fpage><lpage>526</lpage></citation></ref><ref id="pone.0000959-Asano1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asano</surname><given-names>K</given-names></name><name><surname>Merrick</surname><given-names>WC</given-names></name><name><surname>Hershey</surname><given-names>JW</given-names></name></person-group><year>1997</year><article-title>The translation initiation factor eIF3-p48 subunit is encoded by int-6, a site of frequent integration by the mouse mammary tumor virus genome.</article-title><source>J Biol Chem</source><volume>19</volume><fpage>23477</fpage><lpage>23480</lpage><pub-id pub-id-type="pmid">9295280</pub-id></citation></ref><ref id="pone.0000959-Mayeur1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mayeur</surname><given-names>GL</given-names></name><name><surname>Hershey</surname><given-names>JW</given-names></name></person-group><year>2002</year><article-title>Malignant transformation by the eukaryotic translation initiation factor 3 subunit p48 (eIF3e).</article-title><source>FEBS Lett</source><volume>514</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">11904180</pub-id></citation></ref><ref id="pone.0000959-Rasmussen1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>SB</given-names></name><name><surname>Kordon</surname><given-names>E</given-names></name><name><surname>Callahan</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>GH</given-names></name></person-group><year>2001</year><article-title>Evidence for the transforming activity of a truncated Int6 gene, <italic>in vitro</italic>.</article-title><source>Oncogene</source><volume>20</volume><fpage>5291</fpage><lpage>5301</lpage><pub-id pub-id-type="pmid">11536042</pub-id></citation></ref><ref id="pone.0000959-Mack1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mack</surname><given-names>DL</given-names></name><name><surname>Boulanger</surname><given-names>CA</given-names></name><name><surname>Callahan</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>GH</given-names></name></person-group><year>2007</year><article-title>Expression of truncated Int6/eIF3e in mammary alveolar epithelium leads to persistent hyperplasia and tumorigenesis.</article-title><source>Br Can Res,</source><volume>4</volume><fpage>42</fpage></citation></ref><ref id="pone.0000959-Buttitta1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buttitta</surname></name><etal/></person-group><year>2005</year><article-title>Int6 Expression Can Predict Survival in Early-Stage Non-Small Cell Lung Cancer Patients.</article-title><source>Clin Cancer Res</source><volume>11</volume><fpage>3198</fpage><lpage>3204</lpage><pub-id pub-id-type="pmid">15867213</pub-id></citation></ref><ref id="pone.0000959-Marchetti1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marchetti</surname><given-names>A</given-names></name><name><surname>Buttitta</surname><given-names>F</given-names></name><name><surname>Pellegrini</surname><given-names>S</given-names></name><name><surname>Bertacca</surname><given-names>G</given-names></name><name><surname>Callahan</surname><given-names>R</given-names></name></person-group><year>2001</year><article-title>Reduced expression of INT-6/eIF3-p48 in human tumors.</article-title><source>Inter J Onco</source><volume>18</volume><fpage>175</fpage><lpage>179</lpage></citation></ref><ref id="pone.0000959-TraicoffChung1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Traicoff Chung</surname><given-names>JY</given-names></name><name><surname>Braunschweig</surname><given-names>T</given-names></name><name><surname>Mazo</surname><given-names>I</given-names></name><name><surname>Shu</surname><given-names>Y</given-names></name><etal/></person-group><year>2007</year><article-title>Expression of EIF3-p48/INT6, TID1 and Patched in cancer, a profiling of multiple tumor types and correlation of expression.</article-title><source>J Biomed Sci</source><volume>14</volume><fpage>395</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">17385060</pub-id></citation></ref><ref id="pone.0000959-Yen1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>HC</given-names></name><name><surname>Chang</surname><given-names>EC</given-names></name></person-group><year>2003</year><article-title>INT6&#x02013;a link between the proteasome and tumorigenesis.</article-title><source>Cell Cycle</source><volume>2</volume><fpage>81</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">12695651</pub-id></citation></ref><ref id="pone.0000959-Crane1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crane</surname><given-names>R</given-names></name><name><surname>Craig</surname><given-names>R</given-names></name><name><surname>Murray</surname><given-names>R</given-names></name><name><surname>Dunand-Sauthier</surname><given-names>I</given-names></name><name><surname>Humphrey</surname><given-names>T</given-names></name><etal/></person-group><year>2000</year><article-title>A fission yeast homolog of Int-6, the mammalian oncoprotein and eIF3 subunit, induces drug resistance when overexpressed.</article-title><source>Mol Biol Cell</source><volume>10</volume><fpage>3993</fpage><lpage>4003</lpage><pub-id pub-id-type="pmid">11071922</pub-id></citation></ref><ref id="pone.0000959-Jenkins1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>CC</given-names></name><name><surname>Mata</surname><given-names>J</given-names></name><name><surname>Crane</surname><given-names>RF</given-names></name><name><surname>Thomas</surname><given-names>B</given-names></name><name><surname>Akoulitchev</surname><given-names>A</given-names></name><etal/></person-group><year>2005</year><article-title>Activation of AP-1-dependent transcription by a truncated translation initiation factor.</article-title><source>Eukaryotic Cell</source><volume>11</volume><fpage>1840</fpage><lpage>1850</lpage><pub-id pub-id-type="pmid">16278451</pub-id></citation></ref><ref id="pone.0000959-Morris1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>C</given-names></name><name><surname>Jalinot</surname><given-names>P</given-names></name></person-group><year>2005</year><article-title>Silencing of human Int-6 impairs mitosis progression and inhibits cyclin B-Cdk1 activation.</article-title><source>Oncogene</source><volume>24</volume><fpage>1203</fpage><lpage>1211</lpage><pub-id pub-id-type="pmid">15558017</pub-id></citation></ref><ref id="pone.0000959-Buchsbaum1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buchsbaum</surname><given-names>S</given-names></name><name><surname>Morris</surname><given-names>C</given-names></name><name><surname>Bochard</surname><given-names>V</given-names></name><name><surname>Jalinot</surname><given-names>P</given-names></name></person-group><year>2007</year><article-title>Human INT6 interacts with MCM7 and regulates its stability during S phase of the cell cycle.</article-title><source>Oncogene</source><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">16799638</pub-id></citation></ref><ref id="pone.0000959-Chen1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Endler</surname><given-names>A</given-names></name><name><surname>Shibasaki</surname><given-names>F</given-names></name></person-group><year>2007</year><article-title>Mammalian tumor suppressor Int6 specifically targets hypoxia inducible factor 2 alpha for degradation by hypoxia- and pVHL-independent regulation.</article-title><source>J Biol Chem</source><volume>282</volume><fpage>12707</fpage><lpage>12716</lpage><pub-id pub-id-type="pmid">17324924</pub-id></citation></ref><ref id="pone.0000959-Morris2"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>C</given-names></name><name><surname>Wittmann</surname><given-names>J</given-names></name><name><surname>Jack</surname><given-names>HM</given-names></name><name><surname>Jalinot</surname><given-names>P</given-names></name></person-group><year>2007</year><article-title>Human INT6/eIF3e is required for nonsense-mediated mRNA decay.</article-title><source>EMBO Rep. 2007</source><volume>8</volume><fpage>596</fpage><lpage>602</lpage></citation></ref><ref id="pone.0000959-Watkins1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watkins</surname><given-names>SJ</given-names></name><name><surname>Norbury</surname><given-names>CJ</given-names></name></person-group><year>2004</year><article-title>Cell cycle-related variation in subcellular localization of eIF3e/INT6 in human fibroblasts.</article-title><source>Cell Prolif</source><volume>37</volume><fpage>149</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">15030549</pub-id></citation></ref><ref id="pone.0000959-Zhou1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Arslan</surname><given-names>F</given-names></name><name><surname>Wee</surname><given-names>S</given-names></name><name><surname>Krishnan</surname><given-names>S</given-names></name><name><surname>Ivanov</surname><given-names>AR</given-names></name><name><surname>Oliva</surname><given-names>A</given-names></name><name><surname>Leatherwood</surname><given-names>J</given-names></name><name><surname>Wolf</surname><given-names>DA</given-names></name></person-group><year>2005</year><article-title>PCI proteins eIF3e and eIF3m define distinct translation initiation factor 3 complexes.</article-title><source>BMC Biology</source><volume>3</volume><fpage>14</fpage><pub-id pub-id-type="pmid">15904532</pub-id></citation></ref><ref id="pone.0000959-Robu1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robu</surname><given-names>ME</given-names></name><name><surname>Larson</surname><given-names>JD</given-names></name><name><surname>Nasevicius</surname><given-names>A</given-names></name><name><surname>Beiraghi</surname><given-names>S</given-names></name><name><surname>Brenner</surname><given-names>C</given-names></name><etal/></person-group><year>2007</year><article-title>p53 Activation by knockdown technologies.</article-title><source>PloS Genetics</source><volume>3</volume><fpage>0787</fpage><lpage>0801</lpage></citation></ref><ref id="pone.0000959-SeboltLeopold1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sebolt-Leopold</surname><given-names>JS</given-names></name><name><surname>Herrera</surname><given-names>R</given-names></name></person-group><year>2004</year><article-title>Targeting the mitogen-activated protein kinase cascade to treat cancer.</article-title><source>Nat Rev Cancer</source><volume>4</volume><fpage>937</fpage><lpage>947</lpage><pub-id pub-id-type="pmid">15573115</pub-id></citation></ref><ref id="pone.0000959-Schier1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schier</surname><given-names>AF</given-names></name><name><surname>Talbot</surname><given-names>WS</given-names></name></person-group><year>2005</year><article-title>Molecular genetics of axis formation in zebrafish.</article-title><source>Annu Rev Genet</source><volume>39</volume><fpage>561</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">16285872</pub-id></citation></ref><ref id="pone.0000959-BentiresAlj1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bentires-Alj</surname><given-names>M</given-names></name><name><surname>Kontaridis</surname><given-names>MI</given-names></name><name><surname>Neel</surname><given-names>BG</given-names></name></person-group><year>2006</year><article-title>Stops along the RAS pathway in human genetic disease.</article-title><source>Nature Medicine</source><volume>12</volume><fpage>283</fpage><lpage>285</lpage></citation></ref><ref id="pone.0000959-Corson1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corson</surname><given-names>LB</given-names></name><name><surname>Yamanaka</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>KM</given-names></name><name><surname>Rossant</surname><given-names>J</given-names></name></person-group><year>2003</year><article-title>Spatial and temporal patterns of ERK signaling during mouse embryogenesis.</article-title><source>Development</source><volume>130</volume><fpage>4527</fpage><lpage>4537</lpage><pub-id pub-id-type="pmid">12925581</pub-id></citation></ref><ref id="pone.0000959-Wilkie1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilkie</surname><given-names>AO</given-names></name></person-group><year>2005</year><article-title>Bad Bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations.</article-title><source>Cytokine Growth Factor Rev</source><volume>16</volume><fpage>187</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">15863034</pub-id></citation></ref><ref id="pone.0000959-Goldring1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldring</surname><given-names>MB</given-names></name><name><surname>Tsuchimochi</surname><given-names>K</given-names></name><name><surname>Ijiri</surname><given-names>K</given-names></name></person-group><year>2006</year><article-title>The Control of Chondrogenesis.</article-title><source>J Cell Biochem,</source><volume>97</volume><fpage>33</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">16215986</pub-id></citation></ref><ref id="pone.0000959-Graham1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>A</given-names></name><name><surname>Okabe</surname><given-names>M</given-names></name><name><surname>Quinlan</surname><given-names>R</given-names></name></person-group><year>2005</year><article-title>The role of the endoderm in the development and evolution of the pharyngeal arches.</article-title><source>J Anat</source><volume>207</volume><fpage>479</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">16313389</pub-id></citation></ref><ref id="pone.0000959-Murakami1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>S</given-names></name><name><surname>Kan</surname><given-names>M</given-names></name><name><surname>McKeehan</surname><given-names>WL</given-names></name><name><surname>de Crombrugghe</surname><given-names>B</given-names></name></person-group><year>2000</year><article-title>Up-regulation of the chondrogenic <italic>Sox9</italic> gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway.</article-title><source>PNAS,</source><volume>97</volume><fpage>113</fpage><lpage>118</lpage></citation></ref><ref id="pone.0000959-Krens1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krens</surname><given-names>SF</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Spaink</surname><given-names>HP</given-names></name><name><surname>Snaar-Jagalska</surname><given-names>BE</given-names></name></person-group><year>2006</year><article-title>Characterization and expression patterns of the MAPK family in zebrafish</article-title><source>Gene Exp Patterns</source><volume>6</volume><fpage>1019</fpage><lpage>1026</lpage></citation></ref><ref id="pone.0000959-Westerfield1"><label>32</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Westerfield</surname><given-names>M</given-names></name></person-group><year>1995</year><source>The Zebrafish Book</source><publisher-name>The University of Oregon Press</publisher-name></citation></ref><ref id="pone.0000959-Kimmel1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kimmel</surname><given-names>CB</given-names></name><name><surname>Ballard</surname><given-names>WW</given-names></name><name><surname>Kimmel</surname><given-names>SR</given-names></name><name><surname>Ullmann</surname><given-names>B</given-names></name><name><surname>Schilling</surname><given-names>TF</given-names></name></person-group><year>1995</year><article-title>Stages of embryonic development of the zebrafish.</article-title><source>Dev Dyn</source><volume>203</volume><fpage>253</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">8589427</pub-id></citation></ref><ref id="pone.0000959-Shepard1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shepard</surname><given-names>JL</given-names></name><name><surname>Stern</surname><given-names>HM</given-names></name><name><surname>Pfaff</surname><given-names>KL</given-names></name><name><surname>Amatruda</surname><given-names>JF</given-names></name></person-group><year>2004</year><article-title>Analysis of the cell cycle in zebrafish embryos.</article-title><source>Methods Cell Biol</source><volume>76</volume><fpage>109</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">15602874</pub-id></citation></ref><ref id="pone.0000959-Javidan1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Javidan</surname><given-names>Y</given-names></name><name><surname>Schilling</surname><given-names>TF</given-names></name></person-group><year>2004</year><article-title>Development of cartilage and bone.</article-title><source>Methods Cell Biol,</source><volume>76</volume><fpage>415</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">15602885</pub-id></citation></ref><ref id="pone.0000959-NussleinVolhard1"><label>36</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Nusslein-Volhard</surname><given-names>C</given-names></name><name><surname>Dahm</surname><given-names>R</given-names></name></person-group><year>2002</year><source>A Practical Approach</source><publisher-loc>London</publisher-loc><publisher-name>Oxford University Press</publisher-name></citation></ref><ref id="pone.0000959-Patton1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patton</surname><given-names>EE</given-names></name><name><surname>Widlund</surname><given-names>HR</given-names></name><name><surname>Kutok</surname><given-names>JL</given-names></name><name><surname>Kopani</surname><given-names>KR</given-names></name><name><surname>Amatruda</surname><given-names>JF</given-names></name><etal/></person-group><year>2005</year><article-title>BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.</article-title><source>Curr Biol,</source><volume>15</volume><fpage>249</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">15694309</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was funded by a MRC grant to EEP, and by grants from CRUK and the AICR to CJN. Funders had no role in the design or conduct of the study, in the collection, analysis, or interpretation of the data, or in the preparation, review, or approval of the manuscript.</p></fn></fn-group></back></article> 